Gynecologic Oncology

Atezolizumab Plus Bevacizumab/Chemo Fails to Significantly Improve PFS in Ovarian Cancer

September 21st 2020

The addition of atezolizumab to a backbone comprised of bevacizumab and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.

Dr. Coleman on the Clinical Implications of the innovaTV 204 Trial in Cervical Cancer

September 21st 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the clinical implications of the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 trial in women with previously treated recurrent or metastatic cervical cancer.

Tisotumab Vedotin Elicits Encouraging Responses in Recurrent/Metastatic Cervical Cancer

September 21st 2020

Tisotumab vedotin demonstrated an objective response rate of 24% in patients with recurrent and/or metastatic cervical cancer who were previously treated with doublet chemotherapy and bevacizumab, if eligible.

EMA Recommends Approval of Olaparib/Bevacizumab for Frontline Maintenance in HRD+ Advanced Ovarian Cancer

September 21st 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for olaparib as maintenance treatment in adult patients with advanced, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response after first-line platinum-based chemotherapy plus bevacizumab and whose disease has homologous recombination deficiency positivity defined by either a BRCA1/2 mutation and/or genomic instability.

QoL Maintained in Patients With Gynecologic Malignancies Treated on PRIMA Trial

September 20th 2020

Quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo in the PRIMA/ENGOT-OV26/GOG-3012 trial.

Dostarlimab Demonstrates Durable Antitumor Activity in Mismatch Repair Proficient/dMMR Endometrial Cancer

September 20th 2020

Dostarlimab showcased durable antitumor activity in patients with advanced or recurrent DNA mismatch repair deficient and proficient endometrial cancer, with a notable disease control rate and a promising safety profile.

Balstilimab Monotherapy or Plus Zalifrelimab Active in Recurrent/Metastatic Cervical Cancer

September 19th 2020

The investigative PD-1 inhibitor balstilimab as a single agent and combined with the CTLA-4 inhibitor zalifrelimab showed promising objective response rates, regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent/metastatic cervical cancer.

Niraparib Granted Positive EU Opinion for Frontline Maintenance in Advanced Ovarian Cancer

September 18th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for niraparib for frontline maintenance treatment in patients with advanced ovarian cancer who are responsive to platinum-based chemotherapy.

FDA Approves Expanded Use of CINtec PLUS Cytology Test to Prevent Cervical Cancer in HPV+ Women

September 16th 2020

The FDA has approved the expanded use of the CINtec PLUS Cytology assay for women who undergo cervical cancer screening and test positive for high-risk types of human papillomavirus.

Lucitanib/Nivolumab Combo Enters Phase 2 Evaluation for Gynecologic Cancers

September 11th 2020

The first patient has been enrolled on the phase 2 portion of the LIO-1 trial, which will examine the combination of lucitanib plus nivolumab in those with gynecologic cancers.